<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=154171"><dc:title>Potential medical use of fullerenols after two decades of oncology research</dc:title><dc:creator>Injac,	Rade	(Avtor)
	</dc:creator><dc:subject>fullerenol</dc:subject><dc:subject>toxicity</dc:subject><dc:subject>oxidative stress</dc:subject><dc:subject>organ protection</dc:subject><dc:subject>cytostatics</dc:subject><dc:subject>oncology</dc:subject><dc:description>Fullerenes are carbon molecules that are found in nature in various forms. They are composed of hexagonal and pentagonal rings that create closed structures. Almost 4 decades ago, fullerenes were identified in the form of C$_{60}$ and C$_{70}$, and following the award of the Nobel Prize in Chemistry for this discovery in 1996, many laboratories started working on their water-soluble derivatives that could be used in different industries, including pharmaceutical industries. One of the first fullerene forms that was the focus of different research groups was fullerenol, C$_{60}$(OH)$_n$ (n = 2-44). Both in-vitro and in-vivo studies have shown that polyhydroxylate fullerene derivatives can potentially be used as either antioxidative agents or cytostatics (depending on their co-administration, forms, and concentration/dose) in biological systems. The current review aimed to present a critical view of the potential applications and limitations of fullerenols in oncology, as understood from the past 2 decades of research.</dc:description><dc:date>2023</dc:date><dc:date>2024-01-29 14:10:14</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>154171</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
